Story perspectives

ANKTIVA + BCG Beats Gene Therapy in Response, Safety

5/20/2026

Summary

Story summary

ANKTIVA plus BCG achieved a 69.7% anytime complete response and 22.1-month median duration versus 53.4% and 9.7 months for nadofaragene firadenovec-vncg.
Cystectomy-free survival favored ANKTIVA, with overall survival differences not statistically significant.
In analysis, ANKTIVA plus BCG had a 12-month complete response of 49.2% versus 45.9% for TAR-200, a non-significant difference.
Treatment-related adverse events occurred in 61.7% of ANKTIVA patients versus 83.5% for TAR-200, a statistically significant 68% odds reduction.

1 of 1

Story summary

ANKTIVA plus BCG achieved a 69.7% anytime complete response and 22.1-month median duration versus 53.4% and 9.7 months for nadofaragene firadenovec-vncg.
Cystectomy-free survival favored ANKTIVA, with overall survival differences not statistically significant.
In analysis, ANKTIVA plus BCG had a 12-month complete response of 49.2% versus 45.9% for TAR-200, a non-significant difference.
Treatment-related adverse events occurred in 61.7% of ANKTIVA patients versus 83.5% for TAR-200, a statistically significant 68% odds reduction.